Experience of inhaled tobramycin: impact in microbiological and clinical parameters in patients with cystic fibrosis  by Castanhinha, S. et al.
5. Microbiology S37
143 Experience of inhaled tobramycin: impact in microbiological and
clinical parameters in patients with cystic ﬁbrosis
S. Castanhinha1, P. Reis1, J. Fermeiro1, L. Pereira1, C. Barreto1. 1Cystic Fibrosis
Center, Pediatrics Department, Hospital Santa Maria (HSM), Lisbon University,
Lisbon, Portugal
Introduction of inhaled tobramycin (IT) for treatment of pulmonary Pseudomonas
aeruginosa (PA) chronic infection in Cystic Fibrosis (CF) patients (pts), urged the
need to acknowledge the outcome in our Center.
Objectives: Determination of microbiological and clinical evolution after IT.
Methods: Retrospective analysis of CF pts receiving IT (TOBI®) on the last
10 years. Microbiological patterns and clinical parameters were studied 2 years
before and after IT. Chronicity was deﬁned as positivity3 isolates/6 months and
intermittent as positivity1 isolate/year.
Results: 49 pts were studied. PA isolates and chronic infection rates evolution
are shown in Table 1. After 2 years, 7 pts became negative and 2 intermittent.
Resistant PA increased: tobramycin (1 to 11.7%), gentamycin (3.7 to 35.7%),
amycacin (1.6% to 28.5%), ceftazidime (0.5% to 4.1%) and ciproﬂoxacin (4.2% to
16.7%). Staphylococcus aureus chronic infection and MRSA rates increased: 51.4%
to 73.5% and 11.5% to 22.7%, respectively. Burkholderia cepacia rates diminished
(16.7% to 8.2%), chronicity increased (60% to 75%) but diminished later (33%).
Aspergillus ﬂavus emerged and Aspergillus fumigatus increased (0.5% to 9.8%).
Median BMI-percentile, FVC, FEV1 and FEF25−75 transiently improved after IT.
4 pts died on the 2nd year.
Conclusions: We need to be aware of microbiological patterns changes and
increased resistance of CF patients under IT.
We thank the support of HSM Microbiology Department.
Table 1. Evolution of PA isolates and chronic infection rates
2 years before 1 year before 1 year after 2 years after
Isolates 95.7% (n = 43) 100% (n = 49) 81.6% (n = 38) 78.7% (n = 36)
Chronic PA 65.1% 81.3% 84.2% 77.8%
144 Single daily administration of tobramycin (TO) after repeated
multiple-dose treatment: oto- and nephrotoxicity and
drug serum levels
G. Braccini1, I. Lori1, A. Neri1, F. Festini1, S. Campana1, R. Ciuti1, G. Taccetti1.
1Cystic Fibrosis Center, Meyer Children’s Hospital, Florence, Italy
In the past multiple-dose antibiotic treatment has been used to treat pulmonary
exacerbations in cystic ﬁbrosis (CF) patients, even though single daily dosing of
TO has been shown to be as efﬁcacious as multiple doses, with less risk of side
effects. It is advisable to monitor serum levels to try to reduce undesirable effects
of the drug.
Objectives: To evaluate in patients treated with single daily dose of TO:
– mean yearly quantity of intravenous (iv) TO used previously
– serum levels
– the prevalence of oto-and nephrotoxicity
Methods: Retrospective study carried out in CF patients chronically infected
by P. aeruginosa and undergoing therapy with iv TO. Cochlear damage was
evaluated using audiometry and renal damage with creatinine clearance. TO serum
concentrations were measured before the ﬁfth infusion (baseline 1mg/L) and
30min after (peak 20−30mg/L).
Results: 35 patients (19 M, 16 F) (mean age 21.02±10.53) undergoing single-dose
therapy for P. aeruginosa infection were evaluated. The mean yearly quantity of
TO prescribed in previous years was 9431mg (± 2987) and mean daily quantity
was 343.71mg (± 106.93). One patient (2.8%) had baseline TO levels out of
range, 10 (28.5%) had peak values from 20−30mg/L, 22 (62.8%) <20mg/L and
2 (5.7%) >30mg/L. Audiometry was given to 22 (62.8%) of 35 patients (11 M,
11 F) and creatinine clearance was measured in 14 (40%) of 35 patients (4 M, 10
F). Abnormal audiometric pattern was found in 2 (8.6%) patients and abnormal
creatinine clearance in one (6.6%).
Conclusions: Since out of range TO serum levels were found in 2 patients (5.7%),
even those treated with single-dose i.v. TO should be carefully monitored to
minimize untoward effects.
145 Ototoxicity following once daily aminoglycoside administration
in adults with CF
C. Elston1, C. Orchard1, A. Wee1, D. Geddes1, M. Hodson1. 1Adult CF
Department, Royal Brompton Hospital, London, United Kingdom
The incidence of ototoxicity secondary to aminoglycoside use is reported to be
similar for multiple dose (MD) or once daily (OD) administration. Following the
introduction of OD aminoglycoside administration at the Royal Brompton Hospital
an increase in patients presenting with ototoxicity (primarily vestibular toxicity)
was noted.
Aim: To identify risk factors for developing ototoxicity with OD aminoglycoside
administration.
Method: Case notes of all patients receiving OD IV aminoglycosides (10mg/kg)
between December 2005 and June 2006 were reviewed. The CF database was used
to identify patients with ototoxicity in the 5 years before the introduction of the
OD regimen. Factors that may increase the risk of ototoxicity were recorded.
Results: 11 cases were found in the ﬁve years before OD dosing was introduced
(average 2 cases/year). 12/139 patients developed ototoxicity (11 predominantly
vestibular toxicity) following OD aminoglycoside administration. There was no
difference in age, sex, lung function, BMI or aminoglycoside dose between the
ototoxic and asymptomatic groups. The ototoxic group had a higher proportion of
individuals homozygous for DF508 (p = 0.002), more IV aminoglycoside days in
the year preceding OD dosing [47.5 vs 28 days (p = 0.038)] and had received more
courses of aminoglycosides in adulthood [16 vs 6 courses (p< 0.001)]. The OD
dose of aminoglycoside was signiﬁcantly higher than the total MD dose: 595mg
vs 240mg (p = 0.001).
Conclusion: The higher incidence of ototoxicity in patients receiving OD aminogly-
cosides is probably due to both the signiﬁcantly higher dosing schedule used and to
repeated courses of IV aminoglycosides over a lifetime. We recommend caution with
high dose (10mg/kg) OD dosing in patients who have received repeated courses of
aminoglycosides.
146 The effect of long term use of rhDNAse on pulmonary
colonisation in children with cystic ﬁbrosis
H. Bonestroo1, M. Slieker1, H.G. Arets1. 1CF Centre Utrecht, University Medical
Centre Utrecht, Utrecht, Netherlands
rhDNAse has been shown to improve lung function and reduce exacerbation
rates in children with mildly to moderately severe cystic ﬁbrosis. Recent research
hypothesised that this beneﬁcial effect was partly caused by a decrease in bronchial
colonisation. We performed a retrospective case control study to evaluate if this
hypothesised effect of rhDNAse is seen in daily practice.
Methods: From the CF database of the CF centre Utrecht 32 children who used
rhDNAse 2.5mg on a daily base during at least 1.5 years and for each patient a
control CF patient with the same age and not using rhDNAse, were selected.
Primary effect parameter was change in bacterial colonisation during the treatment
period. Therefore the last 3 cultures before starting of rhDNAse and all cultures
during treatment were analysed. Secondary effect parameters were changes in
lungfunction, anthropometry, exacerbations and antibiotic courses before and during
treatment.
Results: At the begining of the study period there were no signiﬁcant differences
between both groups in anthropometry, sex, age and bacterial colonisation, but the
rhDNAse group had signiﬁcantly worse lungfunction (FEV1%pred 78.3 vs 97.7%,
p< 0.05). During 1.5 years treatment there were no signiﬁcant changes in bacterial
colonisation with most important bacteria, but there was a signiﬁcant increase in
the % of patients with Pseudomonas+ cultures within the rhDNAse group (+23%,
p< 0.05) also versus this change in controls. Non signiﬁcant improvements of
lungfunction and exacerbation rates were seen in the rhDNAse group and no
differences in exacerbation rates and anthropometry, compared to controls.
Conclusion: In this retrospective study rhDNAse treatment did not decrease
bacterial colonisation in CF patients
